Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. - Wikidata - wikimedia - TriplyDB

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

http://www.wikidata.org/entity/Q39210427

about

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Mechanically interlocked functionalization of monoclonal antibodies.Challenges and new frontiers in analytical characterization of antibody-drug conjugates.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells

P2860

Q41514180-440765B3-F887-4DC4-A5EC-990AC3782DF6 Q47143718-F172D7F6-BB3A-4515-8B1B-061973CE1435 Q47732625-7B1A3EE0-7745-4358-8873-FBB624C4CAB7 Q47861842-5FF2E6AE-6598-4D09-A075-D26AE0114A2B Q52313806-8EF8A981-6673-4DF9-9945-FA74B4CA653E Q52401505-4DD9CABC-012E-48C8-B139-6843CB7C83B6 Q52578959-7C55BC01-AB3D-4405-BD4C-9892856B749C Q55040576-4A3C3E45-3B56-42B3-99B3-0FABAE681D9A Q58769558-8324135F-4260-4ABA-B845-80D0606AB53F Q59132143-329B8435-4213-4A10-B77A-199C4C4C693C

P2860

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

http://www.wikidata.org/entity/Q39210427

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

@en

Antibody-Drug Conjugates

@nl

type

label

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

@en

Antibody-Drug Conjugates

@nl

prefLabel

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

@en

Antibody-Drug Conjugates

@nl

P1433

Q39210427-138B4140-265C-4379-AA0E-A156E52CD083

P1476

Q39210427-0038A875-64D0-45BD-9AFD-7592B21DCE5F

P2093

Q39210427-06B89B12-0990-445D-A075-97630599765A

Q39210427-8880F3C7-8F98-4D27-A59D-E372ED0FCA3D

P2860

Q39210427-004F223B-3C45-488A-8E44-1510D12AEEE8

Q39210427-00DB3E00-AA8A-4A54-8364-A6B479C03427

Q39210427-03BB1319-05E7-4F52-B169-7C71C5F9F6CD

Q39210427-084FF062-4250-4AD8-BD68-5FBF372CC939

Q39210427-0A30CE41-9B40-4434-AA26-A881AD26439F

Q39210427-1371E358-716C-4366-BFFB-DFDDE70DB733

Q39210427-15D8060B-4A6C-4B54-8DEE-80FDBCC4BCBE

Q39210427-163FE447-C96C-43F5-9603-DC0E195899D6

Q39210427-1950AEE0-7BB9-48FD-B0B8-B7AB430C7ECD

Q39210427-197F75E7-0E0F-4436-85D7-A1F80B678F31

P2888

Q39210427-57730A93-77F8-4BDB-BD8F-D5927F4BAC89

P304

Q39210427-9658F541-4FDE-4E26-B14A-7351E317CB15

P31

Q39210427-035B2780-C520-4301-B5D9-D5FC0765710E

Q39210427-C0CAF343-5B5B-4704-872E-6CBCFE8E01C3

P356

Q39210427-9ACA2028-DD2D-40C7-99BC-35C2A710B08B

P407

Q39210427-BC8F289B-C793-4B5C-BD53-C0D3533125DD

P433

Q39210427-18D78A71-7DF1-4E06-95DD-F5B1DC9AE138

P478

Q39210427-690BF81F-7688-4030-A954-CD04E05638C9

P577

Q39210427-14985EBE-2C39-4432-947E-E6A555DCEA8A

Q39210427-D563D5F8-8AB9-495C-ADE5-D4660E45A996

P698

Q39210427-2B7937FC-E461-4E67-9483-66E42D0A84BC

P921

Q39210427-0C7BDD04-C688-4C0E-98CF-29BEAA7F6A8E

Q39210427-16926F3F-D69D-465C-B51A-06FDA3F0BAFF

Q39210427-340DCE88-BEE9-4FDE-BB1C-EE367D9CFBA2

Q39210427-370C90FC-7D1E-4E97-B0EC-68A50616F1DD

Q39210427-3C245800-15BE-4B63-AC26-D8F940637975

Q39210427-3D76B5BA-3785-4C15-9D0F-D2FF3630FF6C

Q39210427-5421A60E-4995-4278-A32A-4D8AEBB465B9

Q39210427-697EBD6D-8C21-44B9-B8AB-E4CB10FEC6E6

Q39210427-7959845A-BFD3-45D0-AECE-85A41BD2DFA2

Q39210427-863C07B6-7807-41E4-AE0C-9B8A6DE1A77E

P932

Q39210427-26910364-58FC-48C7-86A3-BAAC71F4BC6A

P356

S12325-017-0519-6

P1433

Advances in Therapy

P1476

Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.

@en

P2093

Charles Q Morris

http://www.w3.org/2001/XMLSchema#string

John M Lambert

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

New developments for antibody-drug conjugate-based therapeutic approaches

Continuous cultures of fused cells secreting antibody of predefined specificity

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

P2888

s12325-017-0519-6

P304

1015-1035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-017-0519-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28361465

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

carboxylic acid

monoclonal antibody

polycyclic compound

P932

5427099

http://www.w3.org/2001/XMLSchema#string